Both CBD and THC promise to relieve symptoms and even treat some medical and mental illnesses, but research in this area is still relatively new and more research is needed.
A single small crossover study indicates a potential benefit of the pharmaceutical cannabinoid nabilone. This limited evidence is more applicable to male veterans and contrasts with non-randomized studies that show limited evidence of a statistical association between cannabis use and increased severity of PTSD symptoms in individuals with PTSD. Another study is a Canadian study that examined different formulations of THC and CBD in 42 adults with post-traumatic stress disorder. If these studies are successfully conducted, they will significantly expand the knowledge base, expand the range of cannabinoids evaluated and provide an opportunity to study the consistency of effects across studies. The committee did not identify any good quality primary literature that reported on medical cannabis as an effective treatment to reduce depressive symptoms and that was published after the data collection period of the last published systematic review of good or good quality to address the research problem.
In addition, the larger study was intended to demonstrate a moderate benefit of cannabidiol compared to the antipsychotic drug amisulpride, but included only 60 percent of the planned sample. Therefore, it did not have the statistical power Green Roads CBD Review to determine small or moderate differences between CBD and amisulpride. In general, the evidence is not sufficient to determine whether cannabidiol is an effective treatment for people with schizophrenia or schiophreniform psychosis.
Both good quality reviews identified the same studies, and we focus on the recent review by Whiting et al. . The two RCTs developed by the same research group (Müller-Vahl et al., 2001, 2002, 2003a, b) compared THC capsules with a placebo in 36 patients with Tourette syndrome. The severity of TICS, which was assessed by several measures, and the overall clinical results were improved with THC capsules. These results were evaluated after 2 days (study with uncertain risk of bias) and after 6 weeks (study with high risk of bias). None of the studies adequately described randomization or allocation concealment, and the 6-week study was considered a high risk of bias due to incomplete outcome data.
The two active ingredients seemed to be similar in their effectiveness, without the combination having any additional benefit. Therefore, in this recent research, the cannabinoid again performed just as well as the current standard antiemetic. There are more and more research results that prove the effectiveness of CBD oil in treating some symptoms related to cancer treatment, such as nausea and pain. In a recent study, patients undergoing chemotherapy used CBD oil and found that it helped reduce the side effects of chemotherapy, especially the feeling of nausea. Most of these patients also reported that CBD helped to relieve their discomfort and pain. CBD not only does not make you high, but can also increase your general well-being and improve your quality of life.